API XML

Aop: 164

AOP Title

?


Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse

Short name:

?

Beta-2 adrenergic agonist induction of mesovarian leiomyomas

Graphical Representation

?

Click to download graphical representation template

Authors

?


Cancer AOP Workgroup. National Health and Environmental Effects Research Laboratory, Office of Research and Development, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC. Corresponding author for wiki entry (wood.charles@epa.gov)

Point of Contact

?


Charles Wood   (email point of contact)

Contributors

?


  • Charles Wood

Status

?

Author status OECD status OECD project SAAOP status
Under development: Not open for comment. Do not cite 1.29 Under Development


This AOP was last modified on January 27, 2018 15:34

?

Revision dates for related pages

Page Revision Date/Time
Activation, beta-2 adrenergic receptor September 16, 2017 10:17
Increased activity, beta-2 adrenergic receptor September 16, 2017 10:17
relaxation, smooth muscle December 03, 2016 16:37
Proliferation/Clonal Expansion, smooth muscle September 16, 2017 10:17
Hypertrophy/hyperplasia, smooth muscle December 03, 2016 16:37
Promotion, mesovarian leiomyomas September 16, 2017 10:17
Activation, beta-2 adrenergic receptor leads to Increased activity, beta-2 adrenergic receptor December 03, 2016 16:38
Increased activity, beta-2 adrenergic receptor leads to relaxation, smooth muscle December 03, 2016 16:38
relaxation, smooth muscle leads to Proliferation/Clonal Expansion, smooth muscle December 03, 2016 16:38
Proliferation/Clonal Expansion, smooth muscle leads to Hypertrophy/hyperplasia, smooth muscle December 03, 2016 16:38
Hypertrophy/hyperplasia, smooth muscle leads to Promotion, mesovarian leiomyomas December 03, 2016 16:38

Abstract

?


This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.


Background (optional)

?



Summary of the AOP

?


Events: Molecular Initiating Events (MIE)

?

Key Events (KE)

?

Adverse Outcomes (AO)

?

Sequence Type Event ID Title Short name
1 MIE 1038 Activation, beta-2 adrenergic receptor Activation, beta-2 adrenergic receptor
2 KE 1039 Increased activity, beta-2 adrenergic receptor Increased activity, beta-2 adrenergic receptor
3 KE 1040 relaxation, smooth muscle relaxation, smooth muscle
4 KE 1042 Proliferation/Clonal Expansion, smooth muscle Proliferation/Clonal Expansion, smooth muscle
5 KE 1043 Hypertrophy/hyperplasia, smooth muscle Hypertrophy/hyperplasia, smooth muscle
6 AO 1044 Promotion, mesovarian leiomyomas Promotion, mesovarian leiomyomas

Relationships Between Two Key Events
(Including MIEs and AOs)

?

Title Adjacency Evidence Quantitative Understanding
Activation, beta-2 adrenergic receptor leads to Increased activity, beta-2 adrenergic receptor adjacent High
Increased activity, beta-2 adrenergic receptor leads to relaxation, smooth muscle adjacent High
Proliferation/Clonal Expansion, smooth muscle leads to Hypertrophy/hyperplasia, smooth muscle adjacent High
relaxation, smooth muscle leads to Proliferation/Clonal Expansion, smooth muscle non-adjacent High
Hypertrophy/hyperplasia, smooth muscle leads to Promotion, mesovarian leiomyomas non-adjacent High

Network View

?

 

Stressors

?

Life Stage Applicability

?

Taxonomic Applicability

?

Term Scientific Term Evidence Link
CD-1 mouse Mus musculus High NCBI
SD rat Rattus norvegicus High NCBI

Sex Applicability

?

Sex Evidence
Female High

Overall Assessment of the AOP

?



Domain of Applicability

?


Essentiality of the Key Events

?


Evidence Assessment

?


Quantitative Understanding

?


Considerations for Potential Applications of the AOP (optional)

?



References

?


1. Gibson, J. P., Sells, D. M., Cheng, H. C., and Yuh, L. (1987). Induction of uterine leiomyomas in mice by medroxalol and prevention by propranolol. Toxicologic pathology 15(4), 468-73.

2. Gopinath, C., and Gibson, W. A. (1987). Mesovarian leiomyomas in the rat. Environmental health perspectives 73, 107-13.